GlassScriptPhysician profile
Gannon James Ray
NPI 1659959633
$1,110.85
in general payments reported to CMS, 2019-2025
17 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $86.14 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $170.06 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $149.77 | 2025 | Imfinzi, Calquence |
| Astellas Pharma US INC | $129.63 | 2025 | Vyloy |
| Caris Mpi, INC. | $108.01 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $89.02 | 2025 | |
| Incyte Corporation | $76.78 | 2025 | Monjuvi, Zynyz, Jakafi |
| Janssen Biotech, INC. | $72.08 | 2025 | Balversa, Erleada, Akeega |
| Lilly USA, LLC | $57.07 | 2024 | Mounjaro |
| Genentech USA, INC. | $52.26 | 2025 | Polivy |
| Array Biopharma INC | $46.07 | 2025 | Braftovi, Tukysa, Mektovi |
| Alexion Pharmaceuticals, INC. | $29.07 | 2024 | |
| Beone Medicines USA, INC. | $28.20 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $27.01 | 2025 | Iclusig |
| Merck Sharp & Dohme LLC | $21.31 | 2025 | Lynparza, Keytruda |
| Glaxosmithkline, LLC. | $20.31 | 2025 | Ojjaara |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.19 | 2025 | |
| Puma Biotechnology, INC. | $15.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gannon Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.